EU Accelerated Assessment Tracker
Takeda's Dengue Vaccine Candidate Reverts To Standard Review Timelines
The EU marketing authorization application for Takeda's dengue vaccine candidate is no longer being fast-tracked. Also, four requests for accelerated assessment were decided on at the latest meeting of the European Medicines Agency's drug evaluation committee, the CHMP.